Characterizing the Assessment and Management of Vitamin D Levels in Patients with Osteoporosis in Clinical Practice: A Chart Review Initiative

Table 1

Patient characteristics.

Characteristic	Percentag	Sample size
Gender (female)	87.8%	983
Age		983
<50 years	2.0%
50–59 years	14.5%
60–69 years	30.0%
70–79 years	33.7%
≥80 years	19.7%
BMD based on most recent lowest -score, mean (SD)	−2.16 (1.55)	946
Additional fracture risk factors		977
Previous fragility fracture	27.8%
Systemic glucocorticoids for >3 months	8.5%
Previous fragility fracture and systemic glucocorticoids for >3 months	3.3%
Length of treatment for osteoporosis		980
<1 year	11.3%
1–5 years	43.8%
>5 years	44.9%
Osteoporosis therapy		983
Bisphosphonate	79.0%
Selective estrogen-receptor modulator	3.0%
Hormone therapy	2.3%
Parathyroid hormone	2.2%
Calcitonin	1.3%
Prescribed supplementation		983
Calcium	84.8%
Vitamin D	84.8%

Except for BMD, for which the mean (SD) is presented.
BMD = bone mineral density; SD = standard deviation.